Shares of Keryx Biopharmaceuticals (KERX), a drug developer with a focus on renal disease, had an awful month: Shares were down nearly 40% in September.
What caused the huge downward move? See the presentation below for details.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
